GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Price-to-Owner-Earnings

EQL Pharma AB (FRA:7JK) Price-to-Owner-Earnings : (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Price-to-Owner-Earnings?

As of today (2024-06-23), EQL Pharma AB's share price is €4.19. EQL Pharma AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for EQL Pharma AB's Price-to-Owner-Earnings or its related term are showing as below:

During the past 12 years, the highest Price-to-Owner-Earnings of EQL Pharma AB was 990.00. The lowest was 13.58. And the median was 94.07.


FRA:7JK's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.595
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-23), EQL Pharma AB's share price is €4.19. EQL Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.09. Therefore, EQL Pharma AB's PE Ratio for today is 48.16.

As of today (2024-06-23), EQL Pharma AB's share price is €4.19. EQL Pharma AB's EPS without NRI for the trailing twelve months (TTM) ended in was €0.09. Therefore, EQL Pharma AB's PE Ratio without NRI for today is 48.16.

During the past 12 years, EQL Pharma AB's highest PE Ratio without NRI was 1400.00. The lowest was 15.80. And the median was 46.22.


EQL Pharma AB Price-to-Owner-Earnings Historical Data

The historical data trend for EQL Pharma AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Price-to-Owner-Earnings Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 41.88 -

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.88 - 52.75 93.00 -

Competitive Comparison of EQL Pharma AB's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Price-to-Owner-Earnings falls into.



EQL Pharma AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

EQL Pharma AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.19/-0.06
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EQL Pharma AB  (FRA:7JK) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


EQL Pharma AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB (FRA:7JK) Business Description

Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines